77 results about "Adrenal tissue" patented technology

This invention relates to compositions comprising temozolomide and thalidomide which can be used in the treatment or prevention of cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof. A particular composition comprises temozolomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof. The invention also relates to methods of treating or preventing cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof, which comprise the administration of temozolomide and thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of cancer chemotherapy or radiation therapy which comprise the administration of temozolomide and thalidomide to a patient in need of such reduction or avoidance.

Transcutaneous electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including nasal or paranasal sinus symptoms that resemble an immune-mediated response (“sinus” headaches). The devices and methods may also be used to treat rhinitis, sinusitis, or rhinosinusitis, irrespective of whether those disorders are co-morbid with a headache. They may also be used to treat other disorders that may be co-morbid with migraine or cluster headaches, such as anxiety disorders. In preferred embodiments of the disclosed methods, one or both of the patient's vagus nerves are stimulated non-invasively. In other embodiments, parts of the sympathetic nervous system and / or the adrenal glands are stimulated.

An implantable medical device is provided for the treatment of a variety of disorders. The implantable medical device can be a neurostimulator having a stimulation lead and electrode(s) configured to be implanted on or near neural tissue in communication with the adrenal gland. Application of an electrical waveform to the neural tissue can cause the adrenal gland to release catecholamines to treat hypoglycemia. In other embodiments, chemical, magnetic, optical, or mechanical neuromodulation can be used.

The invention relates to a method for treating, controlling, or preventing cancerous cell phenotypes and growths in an animal involving the administration of gaseous nitric oxide to one or administration sites in a body. The invention generally is capable of treating cancers found in or on the adrenal gland, bladder, bones, brain, breast, cervix, colon, colorectum, esophagus, gastrointestinal tract, heart, kidney, liver, large intestine, lungs, mouth, ovaries, pancreas, parathyroid, pituitary gland, prostate, salivary gland, skin, small intestine, spleen, stomach, thymus, thyroid, testicles, urinary tract, uterus, vagina, and so forth.

Halogenated carboxylic ester derivatives of phenylethyl imidazole, and their method of preparation are disclosed. Radio-halogenated forms of these compounds are ideally suited for positron-imaging of the adrenal glands, as it is known that these compounds demonstrate a selective and high rate of accumulation in the adrenals. The method of preparing these derivatives proceeds by the conversion of a stable, non-radioactive intermediate having trialkylstannyl leaving groups. These intermediates are efficiently converted to the corresponding halogenated forms by substitution of the trialkylstannyl group with the halogen or radiohalogen.

Provided are methods and kits for administering progestogen as a glucocorticoid sensitizer to restore corticosteroid sensitivity or reverse the glucocorticoid insensitivity or enhance glucocorticoid sensitivity, in order to treat one or more glucocorticoid insensitivity related diseases or conditions. For example, these include methods for reversing the glucocorticoid insensitivity in a subject having no history of menstrual cycle-related exacerbation or allergy to self-hormones, particularly progesterone, such as premenstrual or perimenstrual deterioration in the symptoms, e.g., premenstrual worsening of atopic dermatitis or premenstrual exacerbations of asthma, and exhibiting relatively or totally refractory responses to glucocorticoid therapy, e.g., glucocorticoid resistance. The methods and kits provide for the administration of a sex hormone to the subject who is corticosteroid dependent or corticoid resistant or unresponsive or intolerant to corticosteroids.

Transcutaneous electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including nasal or paranasal sinus symptoms that resemble an immune-mediated response (“sinus” headaches). The devices and methods may also be used to treat rhinitis, sinusitis, or rhinosinusitis, irrespective of whether those disorders are co-morbid with a headache. They may also be used to treat other disorders that may be co-morbid with migraine or cluster headaches, such as anxiety disorders. In preferred embodiments of the disclosed methods, one or both of the patient's vagus nerves are stimulated non-invasively. In other embodiments, parts of the sympathetic nervous system and / or the adrenal glands are stimulated.

A method is described for the treatment of obesity or other disorders, by electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by electrically stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an implantable pulse generator. This nerve activation can result in reduced food intake and increased energy expenditure. Reduced food intake may occur through a variety of mechanisms that reduce appetite and cause satiety. Increased adrenal gland hormone levels will result in increased energy expenditure. Fat and carbohydrate metabolism, which are also increased by sympathetic nerve activation, will accompany the increased energy expenditure.

The present invention discloses a pharmaceutical preparation of Chinese herbal medicines which consists of Chinese herbal medicines for tonifying kidney and antiasthma, wherein the Chinese herbal medicines are Perilla Frutescens, Prunus Armeniaca, Glycyrrhiza Uralensis, Scutellaria Baicalensis, Coptis Chinesis, Tusilago Farfara, Stemona Sessilifolia, Fritllaria Cirrhosa, Pheretima Aspergillum, Psoralea Corylifolia, Codonopsis Pilosula, Hordeum Vulgara, Massa Fermentata Medicalis, Schisandra Chinensis, Gypsum. The preparation has been used in China for 20 years, and in Israel for more than 5 years. It has been used to treat thousands of patients suffering from asthma with an effective rate of 93%. The present preparation can relieve cough, expel phlegm, resist airway allergic inflammation reaction, improve pulmonary function, partial pressure of the oxygen in blood and increase CD2, CD4, CD4 / CD8, reduce IgE in blood, and increase CAMP, reduce CGMP, stabilize mast cells, inhibit the release of histamine, which makes it capable of stopping the attack of asthma. As shown with an electron microscope, the preparation protects lung cells, increases lung cells of type 2, and recovers the lung's capacity. It can be applied to the hormone dependent patients for decreasing and ceasing the administration of hormone by adjusting hypothalamic-pituitary-adrenal axis. To further demonstrate the therapeutic effect, a clinical trial carried in the Tel-Hashomer Hospital of Israel proved the preparation can improve asthma significantly.

The invention discloses a Chinese herbal medicinal composition for treating lung cancer. Each dose of the composition at least comprises rehmannia, astragalus, Chinese angelica, ginseng, hoptoad, Indian iphigenia bulb, black nightshade herb, slug and barbated skullcup herb. The materials are added and reduced according to different stages of the lung cancer and different metastases of the lung cancer, and the composition can be prepared in different weight ratios into any formulation in pharmaceuticals . The composition is used for treating early stage of lung cancer, later stage of lung cancer, brain metastasis of the lung cancer, bilateral lung metastasis, bone metastasis, liver metastasis, adrenal gland metastasis and the like. Hundreds of cases of clinical practices prove that the Chinese herbal medicinal composition has remarkable curative effect on the lung cancer, and has longer surviving time than the third generation chemo-therapy medicament.

Methods and compositions for use in treating anxiety are provided. In the subject methods, an effective amount of an agent having ApoE3 activity is administered to a host suffering from an anxiety, e.g. excessive anxiety, unwanted anxiety, an anxiety disorder, etc. Also provided are methods and compositions for modulating adrenal steroidogenesis and / or release, particularly stress induced adrenal steroidogenesis and / or release, and the hippocampal-pituitary-adrenal (HPA) axis. In these methods, an effective amount of an ApoE activity modulating agent, e.g. an ApoE agonist or antagonist, is administered to the host.

The invention provides a preparation method of a brain-soothing hypertension pill. The brain-soothing hypertension pill is prepared by using 100g of baical skullcap roots, 60g of common selfheal fruit-spike, 60g of sophora flower bud, 60g of forged lodestone, 60g of twotooth achyranthes roots, 100g of Chinese angelica, 40g of rehmannia, 40g of danshen roots, 20g of sanguisuga, 60g of uncaria rhynchophylla, 100g of semen cassia, 20g of lumbricus and 40g of nacre as bulk drugs and adopting supercritical extraction and microwave-assisted extraction modes. By adopting the method, the content of baicalin is greatly improved; and the invention also provides application of the brain-soothing hypertension pill in preparation of drugs for inhibiting cell proliferation of rat adrenal pheochromocytoma PC-12.

A Chinese medicine in the form of dispersing tablet or oral liquid for improving immunity and constitution, protecting the function of bone marrow and adrenal cortex, and promoting the function recovery after radiotherapy and chemicotherapy is prepared from lucid ligustrum fruit and astragalus root.

The invention relates to a medicine component used for curing or lightening melancholia or a neurodegeneration disease. The medicine component used for curing or lightening the melancholia or the neurodegeneration disease comprises at least one type of Chinese herbal medicine which is chosen from a group which is composed of ortex phellodendri, radix scutellariae, rhizoma chuanxiong,astragalus, eucommia, Saposhnikovia divaricata and rhizoma corydalis, and the Chinese herbal medicine in the group is capable of promoting rebirth of a neural stem cell and adjusting hypothalamus-infracerebral gland-adrenal gland axis or antiapoptosis. The invention further provides a purpose used for manufacturing the medicine component used for curing or lightening the melancholia or the neurodegeneration disease. The purpose used for manufacturing the medicine component used for curing or lightening melancholia or the neurodegeneration disease comprises at least one type of the Chinese herbal medicine which is capable of promoting rebirth of the neural stem cell and adjusting the hypothalamus-infracerebral gland-adrenal gland axis or the antiapoptosis.

The invention provides a fleece-flower root life-prolonging tablet for treating baldness according to the theory that the baldness is treated in need of treating liver and kidney firstly. The formula of the fleece-flower root life-prolonging tablet is as follows according to the weight ratio: 300-400 parts of polygonum multiflorum, 18-22 parts of rehmannia, 14-20 parts of semen sesami nigrum, 30-50 parts of the root of bidentate achyranthes, 150-200 parts of mulberry, 30-50 parts of fructus ligustri lucidi, 200-250 parts of eclipta, 30-50 parts of folium mori, 70-90 parts of semen cuscutae, 230-280 parts of fructus rosae laevigatae, 30-50 parts of fructus psoraleae, 60-100 parts of phlomis bracteosa royle and 15-25 parts of honeysuckle. The modern pharmacology research shows that the fleece-flower root life-prolonging tablet has the functions of resisting free radicals, preventing lipid peroxidation, reducing activity of monoamine oxidase, enhancing the function of adrenal gland and the like; in addition, the fleece-flower root life-prolonging tablet can lessen the formation of experimental atheromatous plaques and lipid deposition, so as to exert the functions of reducing blood fat and resisting atherosclerosis.

The invention relates to a traditional Chinese medicine preparation for treating climacteric syndrome, comprising the following raw medicines in parts by weight: 10-20 parts of angelica sinensis, 10-20 parts of raspberry, 10-20 parts of motherwort, 10-20 parts of astragali, 10-20 parts of trumpet creeper, 10-20 parts of rose mallow root, 10-20 parts of milkwort, 10-20 parts of mother of pearl, 10-20 parts of spatholobus stem, 10-20 parts of phellodendron bark, 10-20 parts of glossy privet fruit, 10-20 parts of cnidium fruit, 10-20 parts of prepared fleece-flower root, 10-20 parts of dodder, 10-20 parts of white peony root, 10-20 parts of semen biotae shelled, 10-20 parts of curculigo rhizome, 10-20 parts of folium cortex eucommiae, 10-20 parts of flower of silktree, 10-20 parts of root-bark of tree peony and 10-20 parts of wild jujube seed. The traditional Chinese medicine preparation regulates the vegetative nerve function, reduces disturbance of incretion equilibrium, improves psychataxia symptom and maintains homergy, and all medicines are matched to play the efficacies of warming the kidney, invigorating yin and moderately reinforcing yin and yang. The traditional Chinese medicine preparation can stimulate hyperblastosis of adrenal gland, improves the female hormone level, and has better therapeutic action on the climacteric syndrome.

An external medicine for treating dermatitis wherein an adrenocortical steroid is included by a cyclodextrin; and 0.025 to 0.5% by weight of the adrenocortical steroid, 0.2 to 30% by weight of the cyclodextrin, and 0.5 to 55% by weight of dextran or pullulan are dissolved in an aqueous solution containing polysaccharide; and 0.5 to 55% by weight of xyloglucan, trehalose, laminaran, krestin, and pectin are blended. Grape sugar, mutan, lentinan, sodium chloride, and potassium chloride are comprised in the medicine. The medicine has a higher cure effect on atopic dermatitis and psoriasis vulgaris.

The present invention relates to methods for (1) reducing the number and severity of acne lesions on the skin of a mammal; (2) ameliorating the inflammation of acne lesions on the skin of a mammal; (3) improving the skin tone of a mammal, (4) treating skin disorders; (5) treating stress related skin diseases; (6) reducing stress and improving the emotional well being of an acne sufferer; (7) reducing sebaceous gland output; and (8) increasing compliance of the administration of anti-acne products. The method comprises the administration of a sensory regimen in an amount effective to downregulate the activity of the hypothalamus-pituitary-adrenal (HPA) axis in combination with the administration of an anti-acne composition.

The invention relates to a method for preparing a pharmaceutical preparation from salvianolic acid B for preventing and treating osteoporosis. Studies show that the pharmaceutical preparation prepared from the salvianolic acid B has extremely obvious functions for preventing and treating high-conversion type osteoporosis caused by the removal of ovarian rats, can be applied to preventing and treating senile osteoporosis clinically, and particularly has better functions for preventing and treating post-menopausal osteoporosis and the osteoporosis caused by medicaments of glucocorticoid.

The present invention relates to methods for (1) reducing the number and severity of acne lesions on the skin of a mammal; (2) ameliorating the inflammation of acne lesions on the skin of a mammal; (3) improving the skin tone of a mammal, (4) treating skin disorders; (5) treating stress related skin diseases; (6) reducing stress and improving the emotional well being of an acne sufferer; (7) reducing sebaceous gland output; and (8) increasing compliance of the administration of anti-acne products. The method comprises the administration of a sensory regimen in an amount effective to downregulate the activity of the hypothalamus-pituitary-adrenal (HPA) axis in combination with the administration of an anti-acne composition.

The invention discloses an external compound abafenjing drug composition, which comprises the following parts: 0.01-20% abafenjing, 0.005-1% adrenal cortex hormone, medical auxiliary material and antibacterial material. The invention reduces the injury of infected skin, which can treat vaginal candidiasis and vulvopathy.

ACTH analog compounds of the present invention include compounds comprising an ACTH peptide sequence with one or more structural modifications that can have one or more of the following preferred ACTH analog biological functions: (1) reduction of corticosteroid secretion by adrenal membrane in the presence of the ACTH analog compared to unmodified ACTH, (2) reduction of corticosteroid secretion by adrenal membrane in the presence of endogenous ACTH and (3) increased MC-2R binding affinity with reduced activation of the MC-2R receptor compared to unmodified ACTH binding to the MC-2R melanocortin. The ACTH analog compounds of the present invention are therefore useful for treatment or prevention of diseases and disorders related to ACTH, ACTH receptors or corticosteroid secretion, such as premature labor and Cushing's Disease.

The present invention is related to a method, system or process for screening, studying and treating disorders which have a component of mercurial including: autism, autism spectrum disorders, ADD, ADHD, mental retardation, Asperger's syndrome, childhood psychoses, stammering, stuttering, tics, repetitive movements, eating disorders, sleep disorders, enuresis, disturbances of emotion, developmental language disorders, developmental speech disorders, developmental delay, Alzheimer's disease, diabetes, heart disease, obesity, ALS, nephritic syndrome, renal failure, asthma, systemic lupus, autoimmune thyroiditis, rheumatoid arthritis, arthritis, vasculitis, myelitis, glomerulonephritis, optic neuritis, infantile cerebral palsy, epilepsy, migraine, toxic encephalopathy, polyneuropathy, cerebral degenerations, anterior horn cell disease, spinocerebellar disease, extrapyramidal disease, and myopathy, and other related disorders. The invention of a method of screening, studying and treating of these disorders by utilizing the interaction of mercurial with the steroidgenesis pathway and its control by the hypothalamus-pituitary-adrenal axis is described.

The invention belongs to the field of biomedicine, relating to a method for establishing a chronic obstructive pulmonary disease superposition asthma model. By adopting a combined method of Drip endotoxin and smoke in trachea and egg albumin sensitization inspiration, the invention has reliable evaluation on aspects of lung tissue pathology, bronchial reactivity, serum cytokine, hypothalamus-hypophysis-adrenal axis and the like. The result of comparison with the pure chronic obstructive pulmonary disease or asthma model shows that the chronic obstructive pulmonary disease superposition asthma model has the characteristic change of the chronic obstructive pulmonary disease or asthma and weakens or intensifies the charateristic pathologic physiological changes. The invention has the advantages of simple preparation and good reliability and repetitiveness, and meets the disease pathologic physiological characteristics of the chronic obstructive pulmonary disease merger asthma, and can be used for the research of pathogenic mechanisms, prevention and treatment, and the like of the chronic obstructive pulmonary disease merger asthma.

Normal and abnormal diurnal cortisol secretion patterns are identified from human saliva samples by an in vitro method. First and second saliva samples are taken from one human individual at first and second predetermined times during the same day. A first cortisol concentration is determined in the first saliva sample, and a second cortisol concentration is determined in the second saliva sample. An abnormal secretion pattern is then compared to a normal secretion pattern with the help of a fuzzy logic algorithm. A function of the hypothalamic-pituitary-adrenal (HPA) axis is then determined for the human individual. Optionally, a testosterone level is determined from one of the samples and is used in combination with the cortisol concentrations to provide a redefined determination.

The invention relates to the technical field of a processing method of edible meat, in particular to a processing method of the chilled meat. The processing method specially comprises the following steps of quarantine inspection before slaughter, fasting before slaughter, drip washing, tingling through electricity for stunning, bloodletting, machine washing of a pig body, scalding for removing hair, peeling skins, dehairing, burning hair, cutting and repair, flushing before removing internal organs, disembowelling, cutting of around anus, removal of internal organs, numbering, taking out of a small meat block, removal of thyroid, adrenal and lymph node lesions, beheading, removal of feet, removal of oil and the kidney, trimming, cutting of the pig body into two parts, removal of prime condition, first-stage cooling, second-stage cooling and the like. According to the processing method, any additives are not added in the processing course, so that the edible safety of products is guaranteed; besides, the juice flowing rate is greatly reduced, and can be controlled to 1.8% or below; secondly, vacuum packing is adopted, so that the quality guarantee period can achieve 30 days or above, and the refreshing time can achieve 20 days or above; finally, quarantine inspection is performed before slaughter, and the second-stage cooling is performed, so that not only is the cooling rate effectively increased, the energy consumption is reduced, but also the product quality is greatly improved.

The invention relates to an application of Morphine in preparing medicaments for treating the Parkinson disease, in particular to a new medical application of Morphine, belonging to the technical field of medicines. Through a thiazolyl blue (MTT) method, the Morphine is found to be capable of promoting the growth of adrenal gland chromaffin tumor cells (PC12 cells) of rats. The Morphine has the activity of promoting the proliferation of nerve cells and can inhibit nerve cell injuries caused by a Parkinson toxic substance MPP+(1-Methyl-4-Phenylpyridiniumion). Proved by a protein immunoblotting method, the Morphine can induce the expression level of thioredoxin in the PC12 cells, thus the Morphine for protecting the nerve cells from injuries of MPP+ toxicity is related to the induction of the expression of the thioredoxin.

The present invention discloses solid phase synthesis process of adrenal medullarin (27-52). The synthesis process includes the first solid phase Fmoc polypeptide synthesis to graft protective amino acid Fmoc-Ala-OH onto resin, connecting the rest protective amino acids successively, cutting down the synthesized coarse peptide with peptide cutting reagent, and final separating and purifying to obtain the adrenal medullarin (27-52) as the target peptide. The present invention has mild reaction condition, high reaction rate, less side reactions, easy purification, high yield, no corrosion to the equipment and no environmental pollution.

The disclosure relates to pharmaceutical compositions useful in the treatment of adrenal insufficiency in paediatric or elderly subjects.

The invention discloses clyster liquid for treating radioactive enteritis, which is characterized by comprising the following components according to the mixture ratio: 15g of radix arnebiae seu lithospermi, 20g of agrimony, 30g of oldenlandia diffusa, 30g of dandelion, 15g of honeysuckle flower, 15g of rhubarb, 30g of purslane, 20g of garden burnet and 15g of smilax glabra rhizoma, wherein the components can fluctuate up and down by 10-20%. By medicine experiments and clinical test, the clyster liquid has a stronger bacteriostatic action for staphyiococcus aureus, colibacillus, pseudomonas pyocyanea, bacillus dysenteriae, typhoid bacillus and the like, contains various vitamins and trace elements, also can reinforce the adrenocortical function and has the functions of relieving the pain, tranquilizing the mind and inducing sleep, so that the prescription has better functions of resisting inflammation, lessening virulence of any pathogenic organism, resisting tumours, penetrating humidity, immunizing, cooling blood, relieving the stasis of blood and the like. The clyster liquid can be decocted by the hospital instead of a patient, is temporarily heated when being applied and is convenient for treating the patient.